Northwest Biotherapeutics (OTCMKTS:NWBO) Releases Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) announced its earnings results on Friday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.

Northwest Biotherapeutics Trading Up 1.1%

Shares of Northwest Biotherapeutics stock traded up $0.00 during trading hours on Friday, reaching $0.19. 1,431,468 shares of the company’s stock were exchanged, compared to its average volume of 3,070,253. Northwest Biotherapeutics has a fifty-two week low of $0.14 and a fifty-two week high of $0.37. The stock has a market cap of $324.11 million, a P/E ratio of -0.01 and a beta of -0.60. The company has a 50 day moving average of $0.18 and a two-hundred day moving average of $0.21.

About Northwest Biotherapeutics

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.